Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : Evolocumab or None & routes: Subcutaneous

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
Aimovig (1) · Ajovy (1) · Emgality (1) · Repatha (1)
classes:
Anti-CGRP ligand monoclonal antibody (2) · Anti-CGRP receptor monoclonal antibody (1) · [[:Category:Biologics|Biologic]] (1) · [[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (1) · [[:Category:Monoclonal_antibodies|Monoclonal antibody (fully human IgG2)]] (1) · [[:Category:PCSK9_inhibitors|PCSK9 inhibitor]] (1)
mechanism:
None (1) · Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1)
uses:
Preventive treatment of migraine in adults (episodic and chronic) (2) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-0000147C-QINU`"', '"`UNIQ--vote-0000147D-QINU`"', '"`UNIQ--vote-0000147E-QINU`"' (1)
starting dose:
140 mg SC every 2 weeks OR 420 mg SC monthly (3 consecutive injections 5 minutes apart due to volume) (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · 70 mg SC monthly; may increase to 140 mg monthly (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)
preparations:
120 mg/mL prefilled syringe or autoinjector (1) · 140 mg/mL single-use prefilled syringe and SureClick autoinjector; Pushtronex 420 mg/3.5 mL on-body infusor (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · 70 mg/mL or 140 mg/mL prefilled autoinjector (1)
fda max:
140 mg/month (1) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 420 mg/month (1) · 675 mg/quarter (1)
routes: (Click arrow to add another value)
onset:
LDL reduction ~50-60% from baseline at 1-2 weeks (1) · Onset of preventive effect over weeks; some patients respond after first dose (1) · Over weeks (2)
duration:
2-4 weeks per dose (1) · Monthly dosing (2) · Monthly or quarterly dosing (1)
halflife:
~11-17 days'"`UNIQ--ref-0000147F-QINU`"' (1) · ~27 days (1) · ~28 days (1) · ~31 days (1)
bioavailability:
Not formally established (1) · Not formally established (high SC) (1) · ~72% from SC depot'"`UNIQ--ref-00001480-QINU`"' (1) · ~82% SC (1)
pregnancy:
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; avoid (3)
legal:
Rx (3) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 4 results in range #1 to #4.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"